Further studies are needed to identify the factors, like prior response, ethnic origin, liver fibrosis status, or HCV-1 genotype, which could explain the differences observed in the strength of association between SVR and IL28B genotype in treatment-experienced patients receiving either TVR or BOC. Here, IFNL3 is linked to Hepatic fibrosis.